Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AVEO and Astellas Discontinue Breast Cancer Trial

Published: Friday, January 31, 2014
Last Updated: Friday, January 31, 2014
Bookmark and Share
Joint decision to discontinue trial due to insufficient enrollment.

AVEO Oncology today  announced  that AVEO and Astellas Pharma Inc.  have jointly decided to discontinue the BATON ( Biomarker Assessment of Tivozanib in ONcology ) breast  cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO  previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient  recruitment efforts.  

“While we believe in the potential benefits of tivozanib for patients with triple  negative breast cancer, we have decided to discontinue the trial because of low patient  accrual,” stated William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO.  “We want to thank the study investigators and their patients who participated in the  trial for their support.” 

The BATON - BC study initiated patient enrollment in December 2012 in a  randomized, double - blind, multicenter Phase 2 clinical trial, evaluating the efficacy of  tivozanib in combination with paclitaxel compared to placebo in combination with  paclitaxel in patients with locally recurrent or metastatic  triple negative breast cancer  who have received no more than one systemic therapy for advanced or metastatic  breast cancer.  All  committed expenses related to the BATON - BC study are shared  equally  between AVEO and  Astellas.  

Separately, as announced in December 2013, data from a planned interim analysis of  the Phase 2 study of tivozanib in patients with colorectal cancer indicate that the study  is unlikely to meet the primary endpoint in the intent - to - treat patient population. Interim data  are being evaluated, and  AVEO and Astellas are in discussions regarding  next steps.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aveo Inks Exclusive Antibody Deal with Novartis
AVEO announces exclusive worldwide license agreement for the development and commercialization of av-380 and related antibodies.
Tuesday, August 18, 2015
AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
Discovery of HeyL gene expression as biomarker marks critical step in developing targeted therapeutics to inhibit notch pathway.
Thursday, June 18, 2009
AVEO Initiates First Clinical Trial of Novel HGF Antagonist
AVEO initiates first clinical trial of novel HGF antagonist in patients with advanced solid tumors and lymphomas.
Wednesday, September 24, 2008
Human Tissue Transgenic Cancer Model may Offer Significant Advance Toward Modeling Human Cancer
AVEO Pharmaceuticals has created invasive human tumors that develop over time in mice from primary human breast tissue.
Thursday, April 19, 2007
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!